Subscribe to RSS
DOI: 10.1055/s-2001-14779
J.A.Barth Verlag in Medizinverlage Heidelberg GmbH & Co.KG
Hypoxie beim Zervixkarzinom: Pathogenese, Charakterisierung und biologische/klinische Konsequenzen [1]
Tumor hypoxia in cervical cancer: Pathophy-sociological aspects, clinical evidence and consequencesPublication History
Publication Date:
31 December 2001 (online)
Zusammenfassung
Lokal fortgeschrittene Zervixkarzinome weisen in der Mehrzahl (ca. 60 %) hypoxische und anoxische Gewebeareale auf. Die heterogen über den Tumor verteilten Hypoxiebereiche sind Folge struktureller Anomalien der neu gebildeten Tumorgefäße, einer gestörten Durchblutung, vergrößerter Diffusionswege und einer tumor- bzw. therapieassoziierten Anämie. Das Ausmaß der prätherapeutischen Hypoxie ist unabhängig von der klinischen Größe, dem Stadium und dem Differenzierungsgrad des Tumors. Anämie verstärkt die Tumorhypoxie. Vergleicht man den prätherapeutischen Oxygenierungsstatus in Zervixkarzinomen gleichen Stadiums und Differenzierungsgrades, so zeigen sich erhebliche inter-individuelle Unterschiede. Die in Beckenrezidiven gemessenen O2-Druckwerte sind deutlich niedriger als in den Primärtumoren. Etwa 78 % der Lokalrezidive weisen Hypoxieareale auf. Die Existenz hypoxischer Tumorbereiche beeinträchtigt sowohl direkt als auch indirekt (u. a. über Zellzykluseffekte) die Effizienz der Therapie mit schwach-ionisierenden Strahlen und einer Reihe O2-abhängiger Zytostatika. Weiterhin kann die Tumorhypoxie die maligne Progression fördern. Dies erklärt die bedeutende Rolle der Tumorhypoxie als unabhängiger, aussagekräftiger Prognoseparameter für die Lokalkontrolle und Überlebensrate. Darüber hinaus könnte die routinemäßige Erfassung des prätherapeutischen Oxygenierungsstatus Möglichkeiten einer von anderen onkologischen Parametern unabhängigen individuellen Therapieplanung eröffnen.
Tumor hypoxia in cervical cancer: Pathophy-sociological aspects, clinical evidence and consequences
Summary
Approximately 60 % of locally advanced carcinomas in the uterine cervix exhibit hypoxic and/or anoxic tissue areas which are heterogeneously distributed within the tumor mass. Hypoxia is caused by structural and functional abnormalities of the newly formed tumor vessels arising from neovascularization, by a disturbed microcirculation, enlarged diffusion distances and by tumor- or therapy-associated anemias. The extent of pretherapeutically measured hypoxic tissue areas is independent of clinical size, FIGO stage and histopathological grade of squamous cell carcinomas of the uterine cervix. Anemia can intensify tumor hypoxia. O2-tensions in local recurrences are even lower than those in the primary tumors. About 78 % of recurrent tumors exhibit hypoxic tissue areas. Hypoxia is known to directly or indirectly (e. g., via cell cycle effects) affect the therapeutic efficacy of sparsely ionizing radiation and some forms of chemotherapy. Sustained tissue hypoxia may also cause molecular changes that can result in a more malignant phenotype, a process termed malignant progression. Based on this association between tumor hypoxia and malignant progression, tumor oxygenation has proven to be an independent, powerful prognostic factor of local control, overall and disease-free survival. In addition, the routine evaluation of the pretherapeutic oxygenation status may enable individual therapeutic strategies, independent of other oncologic parameters.
Schlüsselwörter
Zervixkarzinom - Oxygenierungsstatus - Hypoxie - maligne Progression - Therapieresistenz - Prognosefaktor
Key words
Carcinoma of the uterine cervix - oxygenation status - hypoxia - malignant progression - therapy resistance - prognostic factor
Literatur
- 1 Bergsjö P, Evans J C. Oxygen tension of cervical carcinoma during the early phase of external irradiation. I. Measurements with a Clark micro electrode. Scand J Clin Lab Invest. 1968; 22 156-166
- 2 Bergsjö P, Evans J C. Oxygen tension of cervical carcinoma during the early phase of external irradiation. II. Measurements with bare platinum micro electrodes. Scand J Clin Lab Invest. 1971; 27 71-82
- 3 Brizel D M, Rosner G L, Prosnitz L R, Dewhirst M W. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys. 1995; 32 1121-1125
- 4 Cooper R A, West C ML, Logue J P, Davidson S E, Miller A, Roberts S, Stratford I J, Honess D J, Hunter R D. Changes in oxygenation during radiotherapy in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1999; 45 119-126
- 5 Dunst J, Hänsgen G, Lautenschläger C, Füchsel G, Becker A. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. Int J Radiat Oncol Biol Phys. 1999; 43 367-373
- 6 Fyles A W, Milosevic M, Wong R, Kavanagh M C, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane T J, Hill R P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998; 48 149-156
-
7 Giaccia A J, Koumenis C, Denko N. The influence of tumor hypoxia on malignant progression. In: Vaupel P, Kelleher DK (Eds). Tumor Hypoxia. Pathophysiology, clinical significance and therapeutic perspectives. Wissenschaftliche Verlagsgesellschaft, Stuttgart 1999; 115-124
- 8 Höckel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: Evaluation by computerized O2 tension measurements. Cancer Res. 1991; 51 6098-6102
- 9 Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein P G, Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993; 26 45-50
- 10 Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56 4509-4515
- 11 Höckel M, Schlenger K, Höckel S, Aral B, Schäffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer. 1998; 97 365-369
- 12 Höckel M, Schlenger K, Höckel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999; 59 4525-4528
-
13 Höckel M, Schlenger K, Höckel S, Vaupel P. Association between tumor hypoxia and malignant progression: The clinical evidence in cancer of the uterine cervix. In: Vaupel P, Kelleher DK (Eds). Tumor Hypoxia. Pathophysiology, clinical significance and therapeutic perspectives. Wissenschaftliche Verlagsgesellschaft, Stuttgart 1999; 65-74
- 14 Knocke T H, Weitmann H D, Feldmann H J, Selzer E, Pötter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999; 53 99-104
- 15 Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest. 1968; 106 (Suppl) 145-157
- 16 Lartigau E, Martin L, Lambin P, Haie-Meder C, Gerbaulet A, Eschwege F, Guichard M. Mesure de la pression partielle en oxygène dans des tumeurs du col utérin. Bull Cancer/Radiother. 1992; 79 199-206
- 17 Lyng H, Sundfor K, Tropé C, Rofstad E K. Oxygen tension and vascular density in human cervix carcinoma. Br J Cancer. 1996; 74 1559-1563
- 18 Lyng H, Sundfor K, Tanum G, Rofstad E K. Oxygen tension in primary tumours of the uterine cervix and lymph node metastases of the head and neck. Adv Exp Med Biol. 1997; 428 55-60
- 19 Semenza G L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000; 88 1474-1480
- 20 Sundfor K, Lyng H, Rofstad E K. Oxygen tension and vascular density in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Acta Oncol. 1998; 37 665-670
- 21 Sundfor K, Lyng H, Rofstad E K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer. 1998; 78 822-827
- 22 Sundfor K, Lyng H, Tropé C G, Rofstad E K. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol. 2000; 54 101-107
- 23 Sutherland R M, Ausserer W A, Murphy B J, Laderoute K R. Tumor hypoxia and heterogeneity: Challenges and opportunities for the future. Semin Radiat Oncol. 1996; 6 59-70
- 24 Sutherland R M. Tumor hypoxia and gene expression. Implications for malignant progression and therapy. Acta Oncol. 1998; 37 567-574
- 25 Vaupel P, Schlenger K, Knoop C, Höckel M. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991; 51 3316-3322
- 26 Vaupel P, Thews O, Kelleher D K, Höckel M. Oxygenation of human tumors: The Mainz experience. Strahlenther Onkol. 1998; 174 (Suppl IV) 6-12
-
27 Vaupel P, Kelleher D K. Tumor Hypoxia. Pathophysiology, clinical significance and therapeutic perspectives. (Eds). Wissenschaftliche Verlagsgesellschaft, Stuttgart 1999
- 28 Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad E K, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000; 60 916-921
- 29 Wong R KW, Fyles A, Milosevic M, Pinitilie M, Hill R P. Heterogeneity of polarographic oxygen tension measurements in cervix cancer: An evaluation of within and between tumor variability, probe position, and track depth. Int J Radiat Oncol Biol Phys. 1997; 39 405-412
1 Gefördert durch die Deutsche Krebshilfe (70-1920 Va 2)
Univ.-Prof. Dr. med. Peter VaupelM.A./Univ. Harvard
Institut für Physiologie und Pathophysiologie
Universität Mainz
Duesbergweg 6
D-55099 Mainz